• Cell Senescence β-Galactosidase Staining Kit Guide

  2026-08-28

  Learn how the Cell Senescence β-Galactosidase Staining Kit converts SA-β-Gal activity into a practical senescent cell detection workflow. This guide connects assay chemistry with senolytic screening, controls, image interpretation, and orthogonal validation.

• SCH772984: Selective ERK1/2 Inhibitor Guide

  2026-08-28

  SCH772984 is an ATP-competitive ERK1/2 inhibitor with nanomolar biochemical potency and reported activity in BRAF-, NRAS-, and KRAS-mutant tumor models. Its selective pathway pharmacology supports mechanistic cell studies, while the supplied evidence does not establish efficacy in nasopharyngeal carcinoma.

• ONX-0914 (PR-957) Immunoproteasome Workflows

  2026-08-27

  ONX-0914 (PR-957) enables selective LMP7 interrogation across PBMC cytokine assays, autoimmune disease models, and airway epithelial infection studies. Its strongest value is experimental discrimination: researchers can separate β5i-dependent immune regulation from constitutive proteasome activity while pairing pharmacology with genetic controls.

• Baicalin Methyl Ester in Intestinal Barrier Research

  2026-08-27

  Baicalin methyl ester is an esterified derivative of baicalin studied for protection against LPS-induced intestinal barrier damage. Reported activity includes modulation of the P65/TNF-α/MLCK/ZO-1 axis, improved tight-junction markers, and reduced inflammatory and permeability-associated readouts in preclinical models.

• Rosiglitazone: PPARγ Workflows for Metabolic Research

  2026-08-26

  Rosiglitazone, also known as Brl-49653, enables controlled PPARγ activation in adipogenesis, insulin-resistance, and rare lipodystrophy models. This workflow-focused guide combines receptor assays, mitochondrial readouts, and practical troubleshooting for stronger mechanistic conclusions.

• PPT: Selective ERα Signaling Workflows

  2026-08-26

  PPT (Propyl Pyrazole Triol) enables controlled activation of ERα while helping researchers separate ERα-driven biology from ERβ-associated responses. This guide translates that selectivity into practical workflows for gene-expression studies, uterotrophic assays, and hypothesis-driven breast cancer and female LUAD research.

• CX-4945 Workflows for CK2 Signaling Research

  2026-08-25

  CX-4945 (Silmitasertib) is a practical ATP-competitive CK2 probe for connecting kinase activity with apoptosis, cell-cycle control, and neuroinflammatory signaling. This workflow guide translates evidence from ischemic-stroke toxicology into reproducible cell-based, target-engagement, and pathway-validation experiments.

• ABT-737 and the Spatial Logic of Apoptosis

  2026-08-25

  ABT-737 is more than a potent BCL-2 protein inhibitor: it is a mechanistic probe for understanding how mitochondrial state, anti-apoptotic buffering, and spatial RNA organization shape cancer-cell fate. By combining ABT-737 perturbation with super-resolution imaging, translational researchers can move beyond viability endpoints toward decision-quality evidence about intrinsic apoptosis.

• Lactate–GPR81/FARP1 Drives Insulin-Independent Uptake

  2026-08-24

  The reference study identifies L-lactate as an active metabolic signal that promotes skeletal-muscle glucose uptake without requiring canonical insulin–AKT signaling. Its proposed GPR81–FARP1–RAC1–GLUT4 axis connects exercise-associated lactate production with glucose homeostasis and suggests a mechanistically testable route for studying hyperglycemia and insulin resistance.

• SB743921 Workflow for KSP Inhibition

  2026-08-23

  SB743921 provides a highly selective way to interrogate KSP-dependent mitosis, while time-resolved viability and cell-death measurements reveal whether a response reflects arrest, killing, or both. This workflow helps researchers connect mechanistic assays with cancer-cell screening and tumor xenograft models without overinterpreting a single endpoint.

• Forsythoside E for PKM2 Immunometabolism

  2026-08-22

  Forsythoside E is a mechanistically differentiated tool for linking PKM2 conformation with macrophage metabolism, STAT3 signaling, and inflammatory phenotype. This guide translates its reported activity into practical cell-based and mouse workflows for sepsis-induced liver injury research, with concentration, formulation, and troubleshooting guidance.

• Hyaluronic Acid Scaffolds for Diabetic Wounds

  2026-08-21

  The reference study developed a porcine acellular dermal matrix, hyaluronic acid, and polydopamine-based interpenetrating network sponge containing deferoxamine mesylate for photothermal warm-bath treatment of diabetic wounds. Its combination of extracellular-matrix architecture, sustained cargo release, and near-infrared photothermal activity improved the vascularization-supporting properties of the scaffold, although further validation is needed before clinical translation.

• Insulin–AMPK Control of PINK1 mRNA in Neurons

  2026-08-20

  This bioRxiv preprint identifies insulin–AMPK signaling as a metabolic switch that controls whether Pink1 mRNA remains tethered to mitochondria in neurons. The work connects insulin resistance, SYNJ2BP phosphorylation, and impaired PINK1-dependent mitochondrial quality control, providing a mechanistic framework for studying metabolic regulation of neuronal mitophagy.

• 5X Protein Loading Buffer (Reducing): SDS-PAGE Guide

  2026-08-20

  5X Protein Loading Buffer (Reducing) supports reproducible protein sample preparation by combining SDS, a sulfhydryl reducing agent, buffer salts, and bromophenol blue for denaturing SDS-PAGE workflows. It is intended for reducing electrophoresis conditions and should not be used for native or non-reducing analyses where disulfide bonds or higher-order protein structure must be preserved.

• Excessive Calpain and Offspring Cognition After Surgery

  2026-08-19

  A 2025 Neuropharmacology study identifies excessive calpain activation as a mechanistic link between maternal non-obstetric surgery during pregnancy and cognitive impairment in rat offspring. The work connects calpain activity with reduced hippocampal BDNF/TrkB signaling, synaptic structural disruption, and behavioral deficits, while showing partial rescue with postnatal MDL 28170 or a TrkB agonist.

460 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page